A Phase 3 interventional study of Remternetug and Placebo in Alzheimer's Disease, sponsored by Eli Lilly and Company. Active, not recruiting at 262 sites in 10 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Alzheimer Disease by Eli Lilly and Company — 13 open to participants now, 19 under way, 8 of them phase 3. Alzheimer Disease · Eli Lilly and Company.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 10th largest by planned enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2024, is one of 24 in phase 3, reaches primary completion later than 13 of the 18 other live ones, and was the 88th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →13 of the 99 studies in Alzheimer Disease by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, China, Japan
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Japan, Puerto Rico
Ages 55+
Eli Lilly and Company · Sites in United States, Australia, New Zealand and 1 more country
Ages 50–85
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Eli Lilly and Company · Sites in China
Ages 55–80
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 28 · Phase 3 27 · Phase 4 5
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,400 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 95 across the 95 interventional studies, 859 across the 4 observational. Of the 79 that completed or were terminated, 61 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
3 of the studies in Alzheimer Disease by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026866Phase 3Eli Lilly and CompanyA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | 2027-11 |
| NCT06657768Eli Lilly and CompanyA Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | 2027-07 |
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior or Current Therapies
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Remternetug administered subcutaneously (SC).
Drug: Remternetug
Placebo administered SC.
Drug: Placebo
Administered SC
Also known as: LY3372993
Administered SC
Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)
Time to clinically meaningful progression as measured by CDR. CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease (AD).
Time frame: Baseline to Time to Event up to Week 255
Change from Baseline in Clinical Dementia Rate Box Score (SB)
Change from baseline in Clinical Dementia Rate Box Score (SB) scores range from 0 to 18, with higher scores indicative of more impairment.
Time frame: Baseline, Week 255
Change from Baseline in Montreal Cognitive Assessment (MoCA)
Change from baseline in Montreal Cognitive Assessment (MoCA). Total MoCA score is 0 to 30, with lower scores indicating greater level of impairment.
Time frame: Baseline, Week 255
Change from Baseline in the Category Fluency - Language, Executive Function, Semantic Memory
Change from baseline in the Category Fluency - Language, Executive Function, Semantic Memory. The total score reflects the sum of correct responses generated across all categories presented, with higher values indicating better performance.
Time frame: Baseline, Week 255
Change from Baseline in the Continuous Paired Associate Learning (CPAL)
Change from baseline in Continuous Paired Associate Learning (CPAL) - Visual episodic memory.
Time frame: Baseline, Week 255
Change from Baseline in International Shopping List Test (ISLT) - Verbal Episodic Mem
Change from baseline in the International Shopping List Test (ISLT) - verbal episodic memory.
Time frame: Baseline, Week 255
Change from Baseline in International Daily Symbol Substitution Test-Medicines (iDSSTm) - Complex Attention Memory
Change from baseline in the International Daily Symbol Substitution Test-Medicines (iDSSTm) - complex attention memory.
Time frame: Baseline, Week 255
Change from Baseline in Cognitive Function Index (CFI)
Change from baseline in the Cognitive Function Index (CFI).
Time frame: Baseline, Week 255
Change from Baseline in Mild Behavioral Impairment Checklist (MBI-C)
Change from baseline in the Mild Behavioral Impairment Checklist (MBI-C) The MBI-C total score range is 0 to 102, with higher scores indicating greater impairment.
Time frame: Baseline, Week 255
Change from Baseline in Alzheimer's Disease Cooperative Study (ADCS) Activities of Daily Living - Prevention Instrument (ADCS-ADL-PI)
Change from baseline in the Activities of Daily Living - Prevention Instrument total scores range from 0 to 54, with higher scores indicating better performance.
Time frame: Baseline, Week 255
Pharmacokinetics: Serum Concentrations of Remternetug
PK: serum concentration of remternetug.
Time frame: Baseline through Week 255
Number of Participants with Treatment Emergent Anti-Drug Antibodies (TE-ADAs)
Number of participants with treatment emergent anti-drug antibodies (TE-ADAs).
Time frame: Baseline through Week 255
Showing the first 100 of 262 sites across 10 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Apr 2029, 54 months after the start.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 54 months is above that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remternetug